Pfizer strikes deal with Sangamo, broadening hemophilia pipeline
NEW YORK (Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront. (Source: Reuters: Health)
Source: Reuters: Health - May 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Africa: Making Circumcision Safer for Young Men With Bleeding Disorders
[The Conversation Africa] Circumcision is the oldest and most frequent surgical procedure in the world. In some cultures, it marks a clear break from childhood to adulthood. But, reports of young men dying during traditional initiation rites due to spontaneous bleeding are devastating. The Conversation Africa's Health and Medicine Editor Joy Wanja Muraya asked Dr Peter Kibet Shikuku for his views on a safe circumcision programme in Kenya for boys with haemophilia - a bleeding disorder. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 20, 2017 Category: African Health Source Type: news

Tanzania: Haemophilia Disorder Remains Silent Killer
[Daily News] As the world marked haemophilia day, 97 per cent of people with the disease do not know if they have it or have never been tested. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 19, 2017 Category: African Health Source Type: news

'You leave your hemophilia at the door': New gene therapy offers hope
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - April 18, 2017 Category: Hospital Management Tags: Hospital News Source Type: news

Genentech reports positive interim data from Phase III trial of emicizumab for haemophilia A
Roche's biotechnology subsidiary Genentech has reported positive interim results from the Phase III HAVEN 2 clinical trial of emicizumab for the treatment of children with haemophilia A and inhibitors to factor VIII. (Source: Drug Development Technology)
Source: Drug Development Technology - April 18, 2017 Category: Pharmaceuticals Source Type: news

Cyclist champion Alex's struggle with haemophilia
Alex Dowsett, from Great Baddow, Essex, won a gold medal at the 2014 Glasgow Commonwealth Games. The cyclist, 28, couldn't take part in many sports at school as it was too 'dangerous'. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2017 Category: Consumer Health News Source Type: news

Roche's emicizumab hemophilia drug shows positive results with children
ZURICH (Reuters) - Roche Holding AG's emicizumab drug for treating hemophilia A showed positive interim results in a phase III study with children with inhibitors to clotting protein factor VIII, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A
Roche announced today interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII. (Source: Roche Media News)
Source: Roche Media News - April 17, 2017 Category: Pharmaceuticals Source Type: news

Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A
Roche announced today interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII. (Source: Roche Investor Update)
Source: Roche Investor Update - April 17, 2017 Category: Pharmaceuticals Source Type: news

FDA Advisory Committee Discusses Biologics License Application (BLA) for Nonacog Beta Pegol for the Treatment of People with Hemophilia B
PLAINSBORO, N.J., April 4, 2017 – Novo Nordisk today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) met to discuss the data submitted to support the Biologics License Application (BLA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 4, 2017 Category: Drugs & Pharmacology Source Type: news

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2017 Category: Global & Universal Source Type: news

Unique Characteristics of the X Chromosome and Related Disorders
This article reviews these unique characteristics and applies their guiding principles in a broad overview to Klinefelter syndrome, ornithine transcarbamylase (OTC) deficiency, hemophilia, and fragile X syndrome. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - March 31, 2017 Category: Pediatrics Authors: Shah, K., DeRemigis, A., Hageman, J. R., Sriram, S., Waggoner, D. Tags: Pediatric Drug Labeling Update Articles Source Type: news

CHMP Backs Orphan Drug Refixia for Hemophilia B CHMP Backs Orphan Drug Refixia for Hemophilia B
Refixia (nonacog beta pegol) is a recombinant coagulation factor IX product for the treatment and prophylaxis of bleeding in patients aged 12 years and older with hemophilia B.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 24, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Shire: Standing Up For Patients
Shire has come a long way from a small pharmaceutical start-up in the UK selling calcium supplements for people with osteoporosis. Now, after its $32bn acquisition of Baxalta last year, it is the largest global biotech focused on rare diseases.“Shire is now the global leader in rare diseases and highly specialized conditions,” saysPerry Sternberg, EVP and Head of US Commercial. “We have been on a four-year journey since Flemming Ørnskov came on as CEO, a real transformation. As a physician, he wanted to focus on innovation and, in his mind, the greatest innovation was in the rare disease area. Ther...
Source: EyeForPharma - March 20, 2017 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Resources on Bleeding Disorders
March is bleeding disorders awareness month. Below are a few resources to get started on educating yourself and others about this important health observance. MedlinePlus Health Topics – includes resources for understanding what it means to have a bleeding disorder, common symptoms, diagnosis and treatment, patient handouts, and links to related genetic conditions. Hemophilia Federation […] (Source: NN/LM Middle Atlantic Region Blog)
Source: NN/LM Middle Atlantic Region Blog - March 6, 2017 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Consumer Health Outreach Public Health Source Type: news

More Than 80 Percent Of Patient Advocacy Groups Accept Industry Money
(Reuters Health) - An examination of more than a hundred of the largest U.S. nonprofit organizations created to improve health and fight disease has found that more than 8 in 10 get financial support from companies involved in the drug, biotechnology and medical device industry. In addition, over a third have at least one industry official on their governing board and, in 12 percent of the 104 organizations analyzed, an industry official was listed as leading the governing board. The tally raises concerns about potential conflicts of interest among groups that claim to be looking out for the best interest of patients but w...
Source: Healthy Living - The Huffington Post - March 3, 2017 Category: Consumer Health News Source Type: news

rFVIIIFc for haemophilia  A has small societal cost in USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2017 Category: Drugs & Pharmacology Source Type: news

Haemophilia: a lifetime in treatment
Since the 1950s, a series of breakthroughs have changed the lives of those suffering from the blood disorder (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 28, 2017 Category: Pharmaceuticals Source Type: news

Plant-made hemophilia therapy shows promise, Penn study finds
(University of Pennsylvania) Researchers from the University of Pennsylvania School of Dental Medicine and University of Florida have developed a therapy to prevent a significant complication of hemophilia treatment. Results in dogs show promise. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2017 Category: Global & Universal Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and'trap'CRISPR/Cas9, reducing its treatment potential. Now, a research team has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2017 Category: Science Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
(University of Massachusetts at Amherst) The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and 'trap' CRISPR/Cas9, reducing its treatment potential. Now, Vincent Rotello's laboratory at UMass Amherst has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 7, 2017 Category: Biology Source Type: news

Ban Sparks Panic Among Refugees Awaiting Urgent Medical Care in U.S. Ban Sparks Panic Among Refugees Awaiting Urgent Medical Care in U.S.
Al Ameen, a 33-year-old Iraqi refugee with hemophilia A has been living in Jordan awaiting medical care in the United States for two years. His condition is so advanced, his doctors have told him, that only a handful of facilities in the world can treat him.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Cambridge gene therapy firm loses half of market cap on study results
Cambridge gene therapy firm Dimension Therapeutics on Tuesday announced disappointing results from a trial of its lead drug, cutting its market cap in half. Dimension (Nasdaq: DMTX) announced preliminary data from a small Phase 1/2 study of a drug for hemophilia B, showing that while the treatment was somewhat effective in boosting a blood-clotting protein, some patients experienced liver toxicity. The safety data appeared to raise serious concerns a mong investors. Shares of Dimension were down… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Cambridge gene therapy firm loses half of market cap on study results
Cambridge gene therapy firm Dimension Therapeutics on Tuesday announced disappointing results from a trial of its lead drug, cutting its market cap in half. Dimension (Nasdaq: DMTX) announced preliminary data from a small Phase 1/2 study of a drug for hemophilia B, showing that while the treatment was somewhat effective in boosting a blood-clotting protein, some patients experienced liver toxicity. The safety data appeared to raise serious concerns a mong investors. Shares of Dimension were down… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 31, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Ban sparks panic among refugees awaiting urgent medical care in U.S.
SAN FRANCISCO/NEW YORK, (Reuters) - Al Ameen, a 33-year-old Iraqi refugee with hemophilia A, a genetic disorder that prevents proper blood clotting, has been living in Jordan awaiting medical care in the United States for two years. His condition is so advanced, his doctors have told him, that only a handful of facilities in the world can treat him. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen ’s hemophilia spinoff launches this week. Here’s what you need to know.
With around 400 employees, $325 million in cash and two drugs on the market that generated nearly $850 million in sales in fiscal 2016, Biogen ’s hemophilia spinoff is not your average startup. The company, called Bioverativ, is set to compete its separation from the Cambridge drugmaker(Nasdaq: BIIB) and launch its own website on Wednesday. Shares of the company are already trading on the Nasdaq under the symbol “BIVVV.” In an inte rview, Bioverativ CEO John Cox, who previously served as Biogen’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 30, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Biogen ’s hemophilia spinoff launches this week. Here’s what you need to know.
With around 400 employees, $325 million in cash and two drugs on the market that generated nearly $850 million in sales in fiscal 2016, Biogen ’s hemophilia spinoff is not your average startup. The company, called Bioverativ, is set to compete its separation from the Cambridge drugmaker(Nasdaq: BIIB) and launch its own website on Wednesday. Shares of the company are already trading on the Nasdaq under the symbol “BIVVV.” In an inte rview, Bioverativ CEO John Cox, who previously served as Biogen’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 30, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Haemophilia: One in five at risk from internal bleeding caused by rare blood disorder
HAEMOPHILIA is an inherited bleeding disorder caused by a deficiency in one of the blood clotting factors. (Source: Daily Express - Health)
Source: Daily Express - Health - January 26, 2017 Category: Consumer Health News Source Type: news

Raising a Child with Hemophilia: Fifth Edition Now Available
LA Kelley Communications' groundbreaking book Raising a Child with Hemophilia celebrates its 25th anniversary with a newly revised fifth edition. The first guidebook about hemophilia written by a...(PRWeb January 26, 2017)Read the full story at http://www.prweb.com/releases/2017/01/prweb14011379.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 26, 2017 Category: Pharmaceuticals Source Type: news

Cancer, hepatitis treatments set for boost as China overhauls drugs list
SHANGHAI (Reuters) - China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia. (Source: Reuters: Health)
Source: Reuters: Health - January 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Sobi begins patient enrolment in A-SURE study haemophilia A treatment
Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - January 23, 2017 Category: Pharmaceuticals Source Type: news

Poisoned, shot and beaten: why cyanide alone may have failed to kill Rasputin
Theories around the death of Grigori Rasputin still abound 100 years after the event. We examine the scientific credibility of some of the claimsThe end of December marked the 100th anniversary ofthe death of Rasputin, the “mad monk of Russia”, or “lover of the Russian queen” if you believe theBoney M song, though you probably shouldn ’t. While the song is undoubtedly a floor-filler, unsurprisingly it is not exactly a reliable historical account of Rasputin’s life.Grigori Yefimovich Rasputin, a mystic and spiritual healer born in Pokrovskoe in Siberia, wielded huge influence over the Rus...
Source: Guardian Unlimited Science - January 13, 2017 Category: Science Authors: Kathryn Harkup Tags: Chemistry Forensic science Source Type: news

With gene therapy closing in on hemophilia, BioMarin expands in North Bay
Rare-disease drug developer BioMarin Pharmaceutical Inc. is expanding its Novato manufacturing facility as it pushes into a final clinical trial for its experimental gene therapy for hemophilia A. The facility, expected to come on line in the third quarter, is significant in the emerging field of gene therapy because only a few companies have taken on the commitment of actually making their drugs in-house. Most gene therapy companies have opted to use contract manufacturers, at least throug h clinical… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 9, 2017 Category: Health Management Authors: Ron Leuty Source Type: news

Spark reels in second $15M payment from Pfizer
Spark Therapeutics said Wednesday it has received a second $15 million payment from Pfizer, this one for hitting pre-specified safety and efficacy development milestones for an experimental gene therapy treatment of hemophilia B the company ’s are co-developing. The gene therapy candidate, called SPK-9001, has received breakthrough therapy and orphan product designations from the Food and Drug Administration. “We continue to make strong, tangible progress with our hemophilia pipeline, and achievement… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2017 Category: American Health Authors: John George Source Type: news

Katherine High talks gene therapy progress for hemophilia & inherited retinopathies
(Mary Ann Liebert, Inc./Genetic Engineering News) Gene therapy has shown some of its most promising early results in treating patients with hemophilia and inherited retinal disorders that cause vision loss and blindness, both important research and drug development targets during the career of Katherine High, M.D., President and Chief Scientific Officer of Spark Therapeutics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2017 Category: Global & Universal Source Type: news

Gene therapy for liver disease advanced to human testing
Amy WallaceNEW ROCHELLE, N.Y., Dec. 30 (UPI) -- Liver-directed gene therapy using adeno-associated viral vectors to treat diseases like hemophilia have moved on to human testing. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 30, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
Title: Researchers Develop Potential Oral Treatment for HemophiliaCategory: Health NewsCreated: 12/29/2016 12:00:00 AMLast Editorial Review: 12/30/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - December 30, 2016 Category: Cardiology Source Type: news

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors
(Mary Ann Liebert, Inc./Genetic Engineering News) Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the therapeutic applications of gene therapy to treat liver disorders and the remaining clinical challenges are examined in a comprehensive review article published in Human Gene Therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 30, 2016 Category: Global & Universal Source Type: news

Potential oral treatment for hemophilia in early stage of development
HealthDay News University of Texas at Austin researchers created an oral treatment for one type of hemophilia, which is a serious, genetic bleeding disorder. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 30, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
Currently, genetic bleeding disorder is treated with injections Source: HealthDay Related MedlinePlus Page: Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 29, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
THURSDAY, Dec. 29, 2016 -- People with hemophilia have to endure painful injections every few days to stay alive, but a newly developed treatment may one day offer a simpler, cheaper and less painful alternative. University of Texas at Austin... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 29, 2016 Category: Journals (General) Source Type: news

Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule LEXINGTON, Massachusetts, December 27, 2016 -- (Healthcare Sales & Marketing Network) -- Shire plc (... Biopharmaceuticals, FDA Shire plc, ADYNOVATE, hemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 27, 2016 Category: Pharmaceuticals Source Type: news

Coming soon to the Nasdaq: Biogen's hemophilia spinoff
The biggest life sciences company based in Massachusetts will soon spawn another publicly traded biotech with a similar ticker symbol. Cambridge-based Biogen (Nasdaq: BIIB) announced in May that it planned to spin off its hemophilia business, and the move was formally approved by the company’s board of directors on Dec. 20. The new firm, named Bioverativ, will start with around 400 employees and will be led by John Cox, who pre viously served as Biogen’s executive vice president of pharmaceutical… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 27, 2016 Category: American Health Authors: Max Stendahl Source Type: news

Coming soon to the Nasdaq: Biogen's hemophilia spinoff
The biggest life sciences company based in Massachusetts will soon spawn another publicly traded biotech with a similar ticker symbol. Cambridge-based Biogen (Nasdaq: BIIB) announced in May that it planned to spin off its hemophilia business, and the move was formally approved by the company’s board of directors on Dec. 20. The new firm, named Bioverativ, will start with around 400 employees and will be led by John Cox, who pre viously served as Biogen’s executive vice president of pharmaceutical… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 27, 2016 Category: Biotechnology Authors: Max Stendahl Source Type: news

Sporting activities and quality of life in children with hemophilia: an observational study - Cuesta-Barriuso R, Torres-Ortu ño A, Pérez-Alenda S, José Carrasco J, Querol F, Nieto-Munuera J.
The objective of this study was to assess the incidence of sports activities in the quality of life as perceived by children with hemophilia. ... (Source: SafetyLit)
Source: SafetyLit - December 26, 2016 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Capsule for severe bleeding disorder moves closer to reality
Researchers are working to develop a pill to treat this serious inherited bleeding disorder. Oral delivery of the treatment--clotting factor IX--would allow individuals with type B hemophilia to swallow a pill rather than be subjected to several weekly injections of factor IX to control potentially fatal bleeding episodes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 23, 2016 Category: Science Source Type: news

Roche boosted by haemophilia drug test
Swiss pharma group says treatment showed signs of outperforming others (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 22, 2016 Category: Pharmaceuticals Source Type: news

Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylax... Biopharmaceuticals Genentech, Roche Group, emicizumab, HAVEN 1, hemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2016 Category: Pharmaceuticals Source Type: news

Roche's emicizumab for haemophilia A meets primary endpoint in phase III study
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII. The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. (Source: World Pharma News)
Source: World Pharma News - December 22, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's emicizumab haemophilia drug succeeds in trial
ZURICH (Reuters) - Roche Holding AG's emicizumab drug for treating haemophilia A showed it worked in a phase III study, the Swiss drugmaker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2016 Category: Consumer Health News Tags: healthNews Source Type: news